Home Business CAR-T cell therapy benefits limited to few patients because of ‘Insurance Snags’

CAR-T cell therapy benefits limited to few patients because of ‘Insurance Snags’

Few Patients Get CAR T Cells Because of 'Insurance Snags' according to Medscape


Two CAR T-cell therapies has now been approved in the United States ― tisagenlecleucel (Kymriah, Novartis), for certain pediatric and young adult patients who have a form of acute lymphoblastic leukemia, and axicabtagene ciloleucel (Yescarta, Kite/Gliead) for adult patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma who are ineligible for autologous stem cell transplant.

“The biggest issue has been insurance, particularly with Medicare and Medicaid,” said Michael Bishop, MD, director of the cellular therapy program at the University of Chicago Medicine, Illinois, who was quoted in the article. “There’s no billing codes for this. It’s been difficult, to be very blunt.”


Previous articleGBT Receives FDA Breakthrough Therapy Designation for Voxelotor for Treatment of Sickle Cell Disease (SCD)
Next articleAbeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa
CellTribune.com provides business and research news updates for the cell and gene therapy industry. CellTribune follows the companies and people who drive innovation in this exciting technology. The goal of CellTribune is to be recognized as the media leader and the go-to source for originally-reported, quality news coverage in this industry. We strive to become the link between budding companies, analysts and institutional investors. Submit your press release to Cell Tribune for immediate publication.